BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 11314037)

  • 1. Cytotoxicity of Tumor necrosis factor related apoptosis-inducing ligand towards Ewing's sarcoma cell lines.
    Kumar A; Jasmin A; Eby MT; Chaudhary PM
    Oncogene; 2001 Feb; 20(8):1010-4. PubMed ID: 11314037
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ewing's sarcoma family tumors are sensitive to tumor necrosis factor-related apoptosis-inducing ligand and express death receptor 4 and death receptor 5.
    Mitsiades N; Poulaki V; Mitsiades C; Tsokos M
    Cancer Res; 2001 Mar; 61(6):2704-12. PubMed ID: 11289151
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sensitivity of Ewing's sarcoma to TRAIL-induced apoptosis.
    Kontny HU; Hämmerle K; Klein R; Shayan P; Mackall CL; Niemeyer CM
    Cell Death Differ; 2001 May; 8(5):506-14. PubMed ID: 11423911
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chemotherapeutic agents sensitize sarcoma cell lines to tumor necrosis factor-related apoptosis-inducing ligand-induced caspase-8 activation, apoptosis and loss of mitochondrial membrane potential.
    Hotta T; Suzuki H; Nagai S; Yamamoto K; Imakiire A; Takada E; Itoh M; Mizuguchi J
    J Orthop Res; 2003 Sep; 21(5):949-57. PubMed ID: 12919886
    [TBL] [Abstract][Full Text] [Related]  

  • 5. NF-kappaB-independent actions of sulfasalazine dissociate the CD95L- and Apo2L/TRAIL-dependent death signaling pathways in human malignant glioma cells.
    Hermisson M; Weller M
    Cell Death Differ; 2003 Sep; 10(9):1078-89. PubMed ID: 12934082
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sensitization of tumor cells to Apo2 ligand/TRAIL-induced apoptosis by inhibition of casein kinase II.
    Ravi R; Bedi A
    Cancer Res; 2002 Aug; 62(15):4180-5. PubMed ID: 12154014
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enhanced apoptosis of glioma cell lines is achieved by co-delivering FasL-GFP and TRAIL with a complex Ad5 vector.
    Rubinchik S; Yu H; Woraratanadharm J; Voelkel-Johnson C; Norris JS; Dong JY
    Cancer Gene Ther; 2003 Nov; 10(11):814-22. PubMed ID: 14605667
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential induction of apoptosis by tumor necrosis factor-related apoptosis-inducing ligand in human ovarian carcinoma cells.
    Lane D; Cartier A; L'Espérance S; Côté M; Rancourt C; Piché A
    Gynecol Oncol; 2004 Jun; 93(3):594-604. PubMed ID: 15196850
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Resistance to TRAIL-induced apoptosis in ovarian cancer cell lines is overcome by co-treatment with cytotoxic drugs.
    Tomek S; Horak P; Pribill I; Haller G; Rössler M; Zielinski CC; Pils D; Krainer M
    Gynecol Oncol; 2004 Jul; 94(1):107-14. PubMed ID: 15262127
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stat1-dependent induction of tumor necrosis factor-related apoptosis-inducing ligand and the cell-surface death signaling pathway by interferon beta in human cancer cells.
    Choi EA; Lei H; Maron DJ; Wilson JM; Barsoum J; Fraker DL; El-Deiry WS; Spitz FR
    Cancer Res; 2003 Sep; 63(17):5299-307. PubMed ID: 14500361
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Regulation of TRAIL-induced apoptosis by ectopic expression of antiapoptotic factors.
    Aggarwal BB; Bhardwaj U; Takada Y
    Vitam Horm; 2004; 67():453-83. PubMed ID: 15110190
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Type I interferon and TNFalpha cooperate with type II interferon for TRAIL induction and triggering of apoptosis in SK-N-MC EWING tumor cells.
    Abadie A; Besançon F; Wietzerbin J
    Oncogene; 2004 Jun; 23(28):4911-20. PubMed ID: 15077162
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differential roles of RelA (p65) and c-Rel subunits of nuclear factor kappa B in tumor necrosis factor-related apoptosis-inducing ligand signaling.
    Chen X; Kandasamy K; Srivastava RK
    Cancer Res; 2003 Mar; 63(5):1059-66. PubMed ID: 12615723
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Butyrate sensitizes human colon cancer cells to TRAIL-mediated apoptosis.
    Hernandez A; Thomas R; Smith F; Sandberg J; Kim S; Chung DH; Evers BM
    Surgery; 2001 Aug; 130(2):265-72. PubMed ID: 11490359
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Induction and regulation of tumor necrosis factor-related apoptosis-inducing ligand/Apo-2 ligand-mediated apoptosis in renal cell carcinoma.
    Griffith TS; Fialkov JM; Scott DL; Azuhata T; Williams RD; Wall NR; Altieri DC; Sandler AD
    Cancer Res; 2002 Jun; 62(11):3093-9. PubMed ID: 12036919
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Regulation of TNF-related apoptosis-inducing ligand-mediated death-signal pathway in human beta cells by Fas-associated death domain and nuclear factor kappaB.
    Ou D; Wang X; Metzger DL; Robbins M; Huang J; Jobin C; Chantler JK; James RF; Pozzilli P; Tingle AJ
    Hum Immunol; 2005 Jul; 66(7):799-809. PubMed ID: 16112027
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Persistent c-FLIP(L) expression is necessary and sufficient to maintain resistance to tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in prostate cancer.
    Zhang X; Jin TG; Yang H; DeWolf WC; Khosravi-Far R; Olumi AF
    Cancer Res; 2004 Oct; 64(19):7086-91. PubMed ID: 15466204
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mechanisms of resistance to TRAIL-induced apoptosis in cancer.
    Zhang L; Fang B
    Cancer Gene Ther; 2005 Mar; 12(3):228-37. PubMed ID: 15550937
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sensitivity of prostate cells to TRAIL-induced apoptosis increases with tumor progression: DR5 and caspase 8 are key players.
    Hesry V; Piquet-Pellorce C; Travert M; Donaghy L; Jégou B; Patard JJ; Guillaudeux T
    Prostate; 2006 Jun; 66(9):987-95. PubMed ID: 16541419
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumor necrosis factor-related apoptosis-inducing ligand-mediated proliferation of tumor cells with receptor-proximal apoptosis defects.
    Baader E; Toloczko A; Fuchs U; Schmid I; Beltinger C; Ehrhardt H; Debatin KM; Jeremias I
    Cancer Res; 2005 Sep; 65(17):7888-95. PubMed ID: 16140959
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.